OMIC Stock - Singular Genomics Systems, Inc.
Unlock GoAI Insights for OMIC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $2.91M | $765,000 | N/A | N/A | N/A |
| Gross Profit | $-558,000 | $-24,000 | $-1,133,000 | $-639,000 | $-350,000 |
| Gross Margin | -19.2% | -3.1% | N/A | N/A | N/A |
| Operating Income | $-102,801,000 | $-93,487,000 | $-61,279,000 | $-27,534,000 | $-12,770,000 |
| Net Income | $-94,820,000 | $-88,271,000 | $-98,889,000 | $-28,663,000 | $-12,341,000 |
| Net Margin | -3257.3% | -11538.7% | N/A | N/A | N/A |
| EPS | $-39.08 | $-37.22 | $-40.95 | $-12.41 | $-5.34 |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 17th 2022 | UBS | Downgrade | Neutral | $4.5← $10 |
| August 10th 2022 | Goldman | Downgrade | Neutral | $3.5 |
| August 10th 2022 | BofA Securities | Downgrade | Underperform | $3 |
Earnings History & Surprises
OMICEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 12, 2025 | — | — | — | — |
Q2 2025 | May 13, 2025 | — | — | — | — |
Q1 2025 | Mar 17, 2025 | — | $-9.61 | — | — |
Q4 2024 | Nov 12, 2024 | $-8.05 | $-6.72 | +16.5% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-8.86 | $-8.57 | +3.3% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.35 | $-10.21 | -2817.1% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-0.34 | $-9.61 | -2726.5% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-11.41 | $-9.31 | +18.4% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-10.51 | $-10.51 | 0.0% | = MET |
Q2 2023 | May 9, 2023 | $-10.21 | $-9.91 | +2.9% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-11.11 | $-8.71 | +21.6% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-11.11 | $-9.91 | +10.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-10.21 | $-10.21 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-10.21 | $-9.31 | +8.8% | ✓ BEAT |
Q1 2022 | Mar 2, 2022 | $-10.51 | $-8.11 | +22.8% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-7.21 | $-7.51 | -4.2% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-0.20 | $-0.43 | -115.0% | ✗ MISS |
Q2 2021 | May 28, 2021 | — | $-3.42 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-10.55 | — | — |
Latest News
Frequently Asked Questions about OMIC
What is OMIC's current stock price?
What is the analyst price target for OMIC?
What sector is Singular Genomics Systems, Inc. in?
What is OMIC's market cap?
Does OMIC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OMIC for comparison